Does orlistat cause acute kidney injury?

被引：13

作者：

Beyea, Michael M. ^{[2
]}

Garg, Amit X. ^{[3
,4
]}

Weir, Matthew A. ^{[1
]}

机构：

[1] Univ Hosp, ALL 139A,339 Windermere Rd, London, ON N6A 5A5, Canada

[2] Univ Western Ontario, Kidney Clin Res Unit, London, ON, Canada

[3] Univ Western Ontario, Kidney Clin Res Unit, Dept Med, Div Nephrol, Toronto, ON, Canada

[4] Inst Clin Evaluat Sci, Toronto, ON, Canada

来源：

THERAPEUTIC ADVANCES IN DRUG SAFETY | 2012年 / 3卷 / 02期

关键词：

acute kidney injury; orlistat;

D O I：

10.1177/2042098611429985

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Orlistat is an inhibitor of gastric and pancreatic lipase with proven efficacy in the augmentation and maintenance of weight loss. Although its use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been associated with acute kidney injury (AKI). In this review, we summarize orlistat's benefits and drawbacks and discuss the body of evidence supporting its role as a cause of AKI. Although we cannot yet draw an unequivocal causal link between orlistat and AKI, there is enough evidence to include orlistat exposure in the clinical assessment of patients with AKI.

引用

页码：53 / 57

页数：5

共 44 条

[11] Obesity and hypertension: two epidemics or one? [J].

Davy, KP ;

Hall, JE .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2004, 286 (05) :R803-R813

[12]

DeLancey S, 2011, FDA ISSUES EARLY COM

[13]

Emanueli A, 1980, Agents Actions Suppl, V7, P318

[14]

Ferraz RRN, 2004, KIDNEY INT, V66, P676, DOI 10.1111/j.1523-1755.2004.00790.x

[15] Orlistat-associated adverse effects and drug interactions - A critical review [J].

Filippatos, Theodosios D. ;

Derdemezis, Christos S. ;

Gazi, Irene F. ;

Nakou, Eleni S. ;

Mikhailidis, Dimitri P. ;

Elisaf, Moses S. .

DRUG SAFETY, 2008, 31 (01) :53-65

[16]

Guerciolini R, 1997, INT J OBESITY, V21, pS12

[17]

HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309

[18]

Hill JO, 1999, AM J CLIN NUTR, V69, P1108

[19] Role of orlistat in the treatment of obese patients with type 2 diabetes - A 1-year randomized double-blind study [J].

Hollander, PA ;

Elbein, SC ;

Hirsch, IB ;

Kelley, D ;

McGill, J ;

Taylor, T ;

Weiss, SR ;

Crockett, SE ;

Kaplan, RA ;

Comstock, J ;

Lucas, CP ;

Lodewick, PA ;

Canovatchel, W ;

Chung, J ;

Hauptman, J .

DIABETES CARE, 1998, 21 (08) :1288-1294

[20] Contribution of dietary oxalate to urinary oxalate excretion [J].

Holmes, RP ;

Goodman, HO ;

Assimos, DG .

KIDNEY INTERNATIONAL, 2001, 59 (01) :270-276

← 1 2 3 4 5 →